- Home
- MESO vs BMEZ Comparison
MESO vs BMEZ Comparison
Compare MESO & BMEZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- BMEZ
- Stock Information
- Founded
- MESO 2004
- BMEZ N/A
- Country
- MESO Australia
- BMEZ United States
- Employees
- MESO N/A
- BMEZ N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- BMEZ Trusts Except Educational Religious and Charitable
- Sector
- MESO Health Care
- BMEZ Finance
- Exchange
- MESO Nasdaq
- BMEZ Nasdaq
- Market Cap
- MESO 1.7B
- BMEZ 1.5B
- IPO Year
- MESO N/A
- BMEZ N/A
- Fundamental
- Price
- MESO $11.60
- BMEZ $14.32
- Analyst Decision
- MESO Buy
- BMEZ
- Analyst Count
- MESO 4
- BMEZ 0
- Target Price
- MESO $18.00
- BMEZ N/A
- AVG Volume (30 Days)
- MESO 304.3K
- BMEZ 391.3K
- Earning Date
- MESO 02-26-2025
- BMEZ 01-01-0001
- Dividend Yield
- MESO N/A
- BMEZ 8.71%
- EPS Growth
- MESO N/A
- BMEZ N/A
- EPS
- MESO N/A
- BMEZ 0.54
- Revenue
- MESO $5,670,000.00
- BMEZ N/A
- Revenue This Year
- MESO $228.57
- BMEZ N/A
- Revenue Next Year
- MESO $356.77
- BMEZ N/A
- P/E Ratio
- MESO N/A
- BMEZ $30.17
- Revenue Growth
- MESO N/A
- BMEZ N/A
- 52 Week Low
- MESO $4.60
- BMEZ $12.93
- 52 Week High
- MESO $22.00
- BMEZ $16.95
- Technical
- Relative Strength Index (RSI)
- MESO 29.90
- BMEZ 27.90
- Support Level
- MESO $13.60
- BMEZ $14.55
- Resistance Level
- MESO $14.45
- BMEZ $15.37
- Average True Range (ATR)
- MESO 0.47
- BMEZ 0.22
- MACD
- MESO -0.08
- BMEZ -0.05
- Stochastic Oscillator
- MESO 3.06
- BMEZ 3.23
Stock Price Comparison Chart: MESO vs BMEZ
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.